ClinicalTrials.gg
CompletedNCT00050960Updated Jul 13, 2012Results posted

Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 3 interventional study of bexarotene with carboplatin and paclitaxel and carboplatin and paclitaxel in Non-small Cell Lung Cancer, sponsored by Eisai Inc.. Completed at 154 sites in 6 countries. Per ClinicalTrials.gov, last updated 2012-07-13.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
612
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 40 under way, 12 of them phase 3. Carboplatin · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 251
612 · median 55
Started
2002
with 15 others
Phase 3
47 of 272
5 open now
Registered
44th of 272
by date

Among the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment of the 251 interventional ones that give a count, is one of 16 that started in 2002, is one of 47 in phase 3, and was the 44th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

Read the detailed description

This study evaluates the use of Targretin capsules (bexarotene) in combination with Carboplatin and Paclitaxel for the treatment of metastatic non-small cell lung cancer in patients who have not yet received chemotherapy for their lung cancer. Every patient receives a platinum-containing chemotherapy every three weeks for at least four chemotherapy cycles (approximately four months). Half of the patients are randomly assigned to receive Targretin capsules once daily in addition to the chemotherapy. The other half is randomized to receive a standard platinum-containing chemotherapy without Targretin capsules.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • NSCLC
  • Targretin
  • Retinoid
  • Bexarotene
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients must have:

  • Pathologic (histologic or cytologic) confirmation of NSCLC
  • Stage IIIB with malignant pleural effusion or Stage IV disease
  • At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy
  • performance status 0 or 1
  • Adequate organ system function
  • Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy).

Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months)

Patients must not have had:

  • Prior chemotherapy for NSCLC
  • Prior platinum-based chemotherapy for any indication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
612 participants (actual)

Study arms

  • Experimental
    bexarotene with carboplatin and paclitaxel

    Drug: bexarotene with carboplatin and paclitaxel

  • Experimental
    carboplatin and paclitaxel

    Drug: carboplatin and paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Time frame: From date of randomization to date of death

07

Results

Posted Aug 24, 2010

Participant flow

Participant flow — Overall Study
MilestoneBexarotene With Carboplatin and PaclitaxelCarboplatin and Paclitaxel
Started306306
Completed42
Not completed302304
Withdrew: Progressive disease13793
Withdrew: Stable disease1948
Withdrew: Partial response1419
Withdrew: Complete response02
Withdrew: Adverse event6261
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject2318
Withdrew: Administrative3146
Withdrew: Non-compliance31
Withdrew: Death1315

Outcome measures

PrimaryOverall Survival
Time frame:
From date of randomization to date of death
Reported as:
Median · Months
Overall Survival
MonthsBexarotene With Carboplatin and PaclitaxelCarboplatin and Paclitaxel
Overall Survival8.5 (7.7 to 9.3)9.2 (8.3 to 10.5)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bexarotene With Carboplatin and Paclitaxel—256/293 (87.4%)293/293 (100%)
Carboplatin and Paclitaxel—242/295 (82%)295/295 (100%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventBexarotene With Carboplatin and PaclitaxelCarboplatin and Paclitaxel
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)219/293213/295
DehydrationMetabolism and nutrition disorders19/2937/295
DyspnoeaRespiratory, thoracic and mediastinal disorders18/29311/295
AnaemiaBlood and lymphatic system disorders14/2937/295
PyrexiaGeneral disorders12/2938/295
Febrile neutropeniaBlood and lymphatic system disorders11/2939/295
NeutropeniaBlood and lymphatic system disorders11/2932/295
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/2938/295
VomitingGastrointestinal disorders9/2936/295
AstheniaGeneral disorders9/2934/295
Most frequent other events
Showing 10 of 63
Most frequent other events
EventBexarotene With Carboplatin and PaclitaxelCarboplatin and Paclitaxel
HypotriglyceridemiaMetabolism and nutrition disorders168/2936/295
FatigueGeneral disorders156/293137/295
AlopeciaSkin and subcutaneous tissue disorders147/293154/295
AnemiaBlood and lymphatic system disorders147/293112/295
NauseaGastrointestinal disorders147/293140/295
NeutropeniaBlood and lymphatic system disorders138/29371/295
DiarrhoeaGastrointestinal disorders108/29368/295
VomitingGastrointestinal disorders96/29378/295
ConstipationGastrointestinal disorders80/29384/295
ArthralgiaMusculoskeletal and connective tissue disorders78/29368/295

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bexarotene With Carboplatin and PaclitaxelCarboplatin and PaclitaxelTotal
<=18 years000
Between 18 and 65 years166174340
>=65 years140132272
Age Continuous
Age Continuous(years)Bexarotene With Carboplatin and PaclitaxelCarboplatin and PaclitaxelTotal
Mean62.5 ± 9.661.7 ± 10.362.1 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Bexarotene With Carboplatin and PaclitaxelCarboplatin and PaclitaxelTotal
Female103103206
Male203203406
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bexarotene With Carboplatin and PaclitaxelCarboplatin and PaclitaxelTotal
Hispanic or Latino2911
Not Hispanic or Latino304297601
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bexarotene With Carboplatin and PaclitaxelCarboplatin and PaclitaxelTotal
American Indian or Alaska Native000
Asian7310
Native Hawaiian or Other Pacific Islander000
Black or African American232043
White269272541
More than one race000
Unknown or Not Reported527
08

Study locations

154 sites
  • Montgomery Cancer Center, L.L.C.
    Montgomery, Alabama 36106, United States
  • Arizona Clinical Research Center, Inc.
    Tucson, Arizona 85712, United States
  • Bay Area Cancer Research Group, LLC
    Concord, California 94520, United States
  • Compassionate Cancer Care Medical Group, Inc.
    Fountain Valley, California 92708, United States
  • Pacific Coast Hematology/Oncology Medical Group, Inc.
    Fountain Valley, California 92708, United States
  • California Cancer Care, Inc.
    Greenbrae, California 94909, United States
  • Coast Hematology and Oncology Associates
    Long Beach, California 90806, United States
  • Metropolitan Hematology/Oncology Medical Group
    Los Angeles, California 90057, United States
  • Sant P. Chawla, Inc.
    Los Angeles, California 90067, United States
  • UCLA Medical Center
    Los Angeles, California 94115, United States
  • Sutter Gould Medical Foundation
    Modesto, California 95355, United States
  • Medical Oncology Care Associates
    Orange, California 92868, United States
  • Southern California Kaiser Permanente Medical Group
    San Diego, California 92120, United States
  • Sharp Health Care
    San Diego, California 92123, United States
  • UCSF/Mount Zion Comprehensive Cancer Center
    San Francisco, California 94115, United States
  • Medical Group of North County, Inc., San Diego Cancer Center
    Vista, California 92083, United States
  • Rocky Mountain Cancer Centers - Midtown
    Denver, Colorado 80218, United States
  • Eastern Connecticut Hematology & Oncology
    Norwich, Connecticut 06360, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Washington Cancer Institute
    Washington, District of Columbia 20010, United States
  • Comprehensive Cancer Care Specialists of Boca Raton
    Boca Raton, Florida 33428, United States
  • University of Florida/Jacksonville
    Jacksonville, Florida 32209, United States
  • Watson Clinic
    Lakeland, Florida 33805, United States
  • Oncology and Radiation Associates
    Miami, Florida 33133, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34652, United States
  • Florida Oncology Associates
    Orange Park, Florida 32073, United States
  • Cancer Centers of Florida, P.A.
    Orlando, Florida 32806, United States
  • South Florida Oncology & Hematology Consultants
    Plantation, Florida 33324, United States
  • Medical Oncology Associates of Augusta
    Augusta, Georgia 30901, United States
  • Georgia Oncology Partners Research & Education Foundation
    Marietta, Georgia 30060, United States
  • St. Luke's/Mountain State Tumor Institute (MSTI)
    Boise, Idaho 83712, United States
  • Weiss Memorial Hospital
    Chicago, Illinois 60640, United States
  • Northwest Oncology and Hematology, SC
    Elk Grove Village, Illinois 60007, United States
  • Lutheran General Cancer Care Center
    Park Ridge, Illinois 60068, United States
  • Oncology/Hematology Associates of Central Illinois, P.C.
    Peoria, Illinois 61602, United States
  • Hematology Oncology Assoc. of Illinois
    Skokie, Illinois 60077, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Cancer Care Center
    New Albany, Indiana 47150, United States
  • Michiana Hematology-Oncology
    South Bend, Indiana 46601, United States
  • Kansas City Oncology and Hematology Group, Kansas City Cancer Centers
    Overland Park, Kansas 66210, United States
  • Drs. Carroll, Sheth, and Raghavan
    Louisville, Kentucky 40215, United States
  • Southwest Oncology Associates
    Lafayette, Louisiana 70503, United States
  • APMC
    Metairie, Louisiana 70006, United States
  • Louisiana State University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Chesapeake Oncology-Hematology Associates
    Baltimore, Maryland 21225, United States
  • Associates in Oncology/Hematology PC
    Rockville, Maryland 20850, United States
  • Berkshire Hematology Oncology, PC
    Pittsfield, Massachusetts 01201, United States
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • Providence Cancer Institute
    Southfield, Michigan 48075, United States
  • St. Lukes Hospital
    Duluth, Minnesota 55805, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55407, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Hematology Oncology Centers of the Northern Rockies
    Billings, Montana 59101, United States
  • Montana Cancer & Infectious Disease Specialists
    Missoula, Montana 59802, United States
  • Cancer and Blood Specialists of Nevada
    Henderson, Nevada 89014, United States
  • Nevada Cancer Center
    Las Vegas, Nevada 89109, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Orange Medical Group
    East Orange, New Jersey 07018, United States
  • VA New Jersey Health Care System
    East Orange, New Jersey 07018, United States
  • Hematology-Oncology Associates of Northern NJ, PA
    Morristown, New Jersey 07962, United States
  • Somerset Hematology Oncology Associates
    Somerset, New Jersey 08873, United States
  • University of Medicine & Dentistry of NJ, School of Osteopathic Medicine
    Stratford, New Jersey 08084, United States
  • Overlook Oncology Center
    Summit, New Jersey 07901, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • New York Oncology Hematology, P.C., Capital District Hematology Oncology Associates
    Albany, New York 12208, United States
  • Erie Medical Center
    Buffalo, New York 14215, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Arena Oncology Associates
    Great Neck, New York 11021, United States
  • Cancer Institute of Long Island, Inc.
    Great Neck, New York 11023, United States
  • Cancer Research of Long Island, Inc.
    Great Neck, New York 11023, United States
  • Broome Oncology, LLC
    Johnson City, New York 13790, United States
  • New York Presbyterian Hospital, Weill Medical College of Cornell University
    New York, New York 10021, United States
  • Columbia Presbyterian Medical Center
    New York, New York 10032, United States
  • VA Medical Center
    Northport, New York 11768, United States
  • New York Oncology Hematology, P.C., Riverview Cancer Care Medical Associates
    Rexford, New York 12148, United States
  • South Shore Hematology Oncology Associates, PC
    Rockville Centre, New York 11570, United States
  • Raleigh Hematology Oncology Clinic
    Cary, North Carolina 27511, United States
  • Northwest Carolina Oncology and Hematology, P.A.
    Hickory, North Carolina 28602, United States
  • Nashat Y. Gabrail, MD, Inc.
    Canton, Ohio 44718, United States
  • University of Cincinnati, Barrett Cancer Center
    Cincinnati, Ohio 45219, United States
  • Columbus Community Clinical Oncology Program
    Columbus, Ohio 43206, United States
  • Dayton Oncology/Hematology Consultants
    Dayton, Ohio 45439, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Cancer Care Associates - Mercy Campus
    Oklahoma City, Oklahoma 73120, United States
  • Cancer Care Associates
    Tulsa, Oklahoma 74136, United States
  • Oncology/Hematology, Kaiser Permanente Northwest
    Portland, Oregon 97227, United States
  • Oncology Hematology of Lehigh Valley, PC
    Bethlehem, Pennsylvania 18015, United States
  • Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704, United States
  • Charleston Hematology Oncology P.A.
    Charleston, South Carolina 29403, United States
  • Liberty Hematology/Oncology
    Columbia, South Carolina 29203, United States
  • WJB Dorn VA Medical Center
    Columbia, South Carolina 29209, United States
  • Cancer Centers of the Carolinas
    Seneca, South Carolina 29672, United States
  • Santee Hematology/Oncology
    Sumter, South Carolina 29150, United States
  • Thompson Cancer Survival Center
    Knoxville, Tennessee 37916, United States
  • Boston Baskin Cancer Group
    Memphis, Tennessee 38104, United States
  • Texas Oncology, P.A.
    Arlington, Texas 76012, United States
  • South Austin Cancer Center
    Austin, Texas 78745, United States
  • Lone Star Oncology Consultants, P.A.
    Austin, Texas 78759, United States

Showing the first 100 of 154 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002, a primary completion of Jul 2004 and a completion of Mar 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2002
First posted
Jan 3, 2003
Start
May 2002
Primary completionActual
Jul 2004
CompletionActual
Mar 2005
Results first posted
Aug 24, 2010
Last update
Jul 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00050960
Lead sponsor
Eisai Inc.
First posted
Jan 3, 2003
Start date
May 2002
Primary completion
Jul 2004
Completion
Mar 2005
Results posted
Aug 24, 2010
Last update
Jul 13, 2012

Study contacts

Mack Mabry, M.D.
study director · Ligand Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bexarotene · Carboplatin · Paclitaxel

Start the discussion